Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchElectra Therapeutics, Inc. announces FDA Fast Track designation for ELA026 to treat secondary hemophagocytic lymphohistiocytosis.
Nov 04, 2024
South San FranciscoManufacturingBiotechnologySustainabilityHealth CareScience And EngineeringMining
Product Description
Electra Therapeutics, Inc. has received FDA Fast Track designation for ELA026, a first-in-class antibody therapy aimed at treating secondary hemophagocytic lymphohistiocytosis, a rare and life-threatening condition. This designation allows for the expedited development and review process to bring this innovative therapy to patients.
Company Information
Company
Electra Therapeutics
Location
230 East Grand Avenue, Suite S-100
South San Francisco, California, United States
About
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Electra Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.